InflaRx price target lowered to $14 from $22 at Guggenheim

Guggenheim analyst Yatin Suneja lowered the firm’s price target on InflaRx (IFRX) to $14 from $22 and keeps a Buy rating on the shares. The firm continues to think that the stock is significantly undervalued and believes “more investors should be paying attention to this name,” adding that it updated its model to reflect value for ANCA-associated vasculitis.